Abstract:The ultimate goal in the management of inherited as well as acquired diseases is a rational therapy with the aim to eliminate the underlying biochemical defects, rather than a symptomatic treatment. Among other approaches somatic gene therapy is a promising candidate to meet these objectives and appears to have the potential to revolutionize modern medicine. Gene therapy is characterized by the transfer of genetic information to a patient through the use of recombinant DNA technology. Several strategies for the treatment of monogenetic disorders as well as chronical diseases like cancer and AIDS have been used in various somatic gene therapy projects. So far, 329 clinical studies (phases I, I/II and II) with over 2500 patients have been initiated worldwide since 1989. No significant toxicity and adverse side effects have been observed. To allow efficient transfer of the therapeutic genes, a variety of gene delivery techniques have been developed based on viral and non-viral vector systems. For the success of this technology it is vital to achieve regulated and sustained expression of foreign genes in specific target tissues. This will be crucial for the widespread application of somatic gene therapy. So far none for the gene delivery systems is able to meet the requirements of safety, efficiency and specificity demonstrating that vector research will be an important focus in the development of optimized transfer methods. From a regulatory point of view pharmaceutical DNA-products can be regarded as drugs and are therefore subject to the same regulations. Human gene therapy must, however, be limited to manipulations affecting somatic, differentiated cells to prevent the transferred gene from being transmitted to the individual's descendants. Applications for the purpose of 'enhancement' and not for the treatment of diseases are also not acceptable. Under these prerequisites, somatic gene therapy does not raise any new ethical concerns and can be interpreted as a special form of an organ transplantation. A comparison of the different regulatory situations of gene therapy in Europe and the United States demonstrates that for the European countries a uniform regulation is desired. Today somatic gene therapy is still in its infancy. It will continue to be scientifically and technically challenging until simple and effective procedures will have been developed. Demonstration of its clinical efficacy especially in the long term will have to be the next step. Looking at the history of biotechnology and the success of the biotechnology industry that is now providing safe and efficient products from recombinant DNA-technology there is little doubt that gene therapy will become a successful treatment for various indications in the next decade. The purpose of this article is to review the current status of the development in somatic gene therapy.

Somatic transgenesis and DNA immunization - Rational alternatives

Somatic transgenesis by immunoglobulin genes

Activation of Cd4 T Cells by Somatic Transgenesis Induces Generalized Immunity of Uncommitted T Cells and Immunologic Memory

Somatic Transgene Immunization with DNA Encoding an Immunoglobulin Heavy Chain

In Vivorole of B Lymphocytes in Somatic Transgene Immunization

Progress for Improving the Immune Response of DNA Vaccine

Somatic Transgenesis (viral Vectors)

Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity

Anti-idiotypic Regulatory Responses Induced by Vaccination with DNA Encoding Murine TCR Valpha5 and Vbeta2.

Immunomechanism and Optimized Strategies of DNA Vaccines

New insights for the development of efficient DNA vaccines

DNA fusion gene vaccines against cancer: from the laboratory to the clinic

DNA Vaccines—How Far From Clinical Use?

DNA Vaccines: Their Formulations, Engineering and Delivery

DNA Vaccines in Pigs: From Immunization to Antigen Identification

704/DNA vaccines leverage cytoplasmic DNA stimulation to promote anti-HIV neutralizing antibody production in mice and strong immune response against alpha-fetoprotein in non-human primates

Successive Site Translocating Inoculation Potentiates DNA/recombinant Vaccinia Vaccination

DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response

Shaping immunity against infectious diseases with multivalent DNA vaccines

Somatic gene therapy. Present situation and future perspective

Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases